SCYNEXIS (SCYX) Competitors $0.71 +0.01 (+1.85%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$0.71 0.00 (-0.14%) As of 08/5/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SCYX vs. SAVA, CRBP, ZURA, COYA, TCRX, ATOS, MGNX, HLVX, IMUX, and ZNTLShould you be buying SCYNEXIS stock or one of its competitors? The main competitors of SCYNEXIS include Cassava Sciences (SAVA), Corbus Pharmaceuticals (CRBP), Zura Bio (ZURA), Coya Therapeutics (COYA), TScan Therapeutics (TCRX), Atossa Genetics (ATOS), MacroGenics (MGNX), HilleVax (HLVX), Immunic (IMUX), and Zentalis Pharmaceuticals (ZNTL). These companies are all part of the "pharmaceutical products" industry. SCYNEXIS vs. Its Competitors Cassava Sciences Corbus Pharmaceuticals Zura Bio Coya Therapeutics TScan Therapeutics Atossa Genetics MacroGenics HilleVax Immunic Zentalis Pharmaceuticals SCYNEXIS (NASDAQ:SCYX) and Cassava Sciences (NASDAQ:SAVA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation. Which has higher earnings & valuation, SCYX or SAVA? SCYNEXIS has higher revenue and earnings than Cassava Sciences. Cassava Sciences is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSCYNEXIS$3.75M7.38-$21.29M-$0.56-1.27Cassava SciencesN/AN/A-$24.34M-$1.50-1.63 Do insiders & institutionals hold more shares of SCYX or SAVA? 54.4% of SCYNEXIS shares are owned by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are owned by institutional investors. 4.9% of SCYNEXIS shares are owned by company insiders. Comparatively, 12.2% of Cassava Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media refer more to SCYX or SAVA? In the previous week, Cassava Sciences had 1 more articles in the media than SCYNEXIS. MarketBeat recorded 1 mentions for Cassava Sciences and 0 mentions for SCYNEXIS. SCYNEXIS's average media sentiment score of 0.00 equaled Cassava Sciences'average media sentiment score. Company Overall Sentiment SCYNEXIS Neutral Cassava Sciences Neutral Do analysts rate SCYX or SAVA? Cassava Sciences has a consensus target price of $54.50, indicating a potential upside of 2,133.61%. Given Cassava Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Cassava Sciences is more favorable than SCYNEXIS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SCYNEXIS 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cassava Sciences 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more volatility & risk, SCYX or SAVA? SCYNEXIS has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of -2.05, indicating that its share price is 305% less volatile than the S&P 500. Is SCYX or SAVA more profitable? Cassava Sciences has a net margin of 0.00% compared to SCYNEXIS's net margin of -1,030.04%. SCYNEXIS's return on equity of -53.47% beat Cassava Sciences' return on equity.Company Net Margins Return on Equity Return on Assets SCYNEXIS-1,030.04% -53.47% -32.86% Cassava Sciences N/A -87.72%-72.05% SummarySCYNEXIS beats Cassava Sciences on 8 of the 14 factors compared between the two stocks. Get SCYNEXIS News Delivered to You Automatically Sign up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SCYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCYX vs. The Competition Export to ExcelMetricSCYNEXISMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.16M$2.53B$5.59B$9.53BDividend YieldN/A1.77%4.73%4.14%P/E Ratio-1.279.1628.9123.88Price / Sales7.38717.24445.9598.82Price / CashN/A159.4135.6858.35Price / Book0.495.078.165.60Net Income-$21.29M$31.61M$3.25B$265.26M7 Day Performance1.30%-0.38%1.16%-0.14%1 Month Performance-3.01%5.79%8.26%6.08%1 Year Performance-63.45%3.58%29.19%24.22% SCYNEXIS Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCYXSCYNEXIS0.4454 of 5 stars$0.71+1.9%N/A-63.2%$27.16M$3.75M-1.2760Upcoming EarningsSAVACassava Sciences3.7668 of 5 stars$2.38+1.3%$54.50+2,189.9%-93.0%$113.52MN/A-1.5930News CoveragePositive NewsCRBPCorbus Pharmaceuticals4.7436 of 5 stars$9.59+3.6%$50.88+430.5%-83.8%$113.31MN/A-2.2740News CoverageEarnings ReportHigh Trading VolumeZURAZura Bio3.8149 of 5 stars$1.62-1.2%$14.33+784.8%-57.3%$112.14MN/A-2.313News CoveragePositive NewsUpcoming EarningsCOYACoya Therapeutics1.9591 of 5 stars$6.62-0.7%$16.50+149.2%+9.9%$111.56M$3.55M-6.196Upcoming EarningsTCRXTScan Therapeutics3.7206 of 5 stars$1.87-3.1%$7.80+317.1%-72.0%$109.22M$2.82M-1.72100Upcoming EarningsATOSAtossa Genetics2.5851 of 5 stars$0.82-2.7%$6.17+654.7%-30.0%$108.49MN/A-3.898News CoverageUpcoming EarningsMGNXMacroGenics4.2423 of 5 stars$1.67-2.3%$5.71+242.2%-52.8%$107.88M$149.96M-1.88430HLVXHilleVax1.74 of 5 stars$2.13-0.9%$2.00-6.1%+28.1%$107.80MN/A-0.9920News CoverageIMUXImmunic2.9683 of 5 stars$1.08-3.6%$7.50+594.4%-21.5%$107.32MN/A-0.8870News CoverageZNTLZentalis Pharmaceuticals2.2672 of 5 stars$1.44-2.0%$8.37+481.0%-58.9%$105.77M$67.43M-0.46160Positive NewsUpcoming Earnings Related Companies and Tools Related Companies SAVA Alternatives CRBP Alternatives ZURA Alternatives COYA Alternatives TCRX Alternatives ATOS Alternatives MGNX Alternatives HLVX Alternatives IMUX Alternatives ZNTL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCYX) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SCYNEXIS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SCYNEXIS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
